BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2025
0mins
Source: Globenewswire
BioAge Labs Updates: BioAge Labs is advancing its oral NLRP3 inhibitor BGE-102 for metabolic diseases, with initial clinical data expected in the second half of 2025, while also progressing next-generation APJ agonists after discontinuing azelaprag due to safety concerns.
Strategic Collaborations and Financials: The company has formed partnerships with Novartis and Lilly to explore novel therapies targeting metabolic aging, and reported a net loss of $71.1 million for 2024, with sufficient cash reserves to fund operations through 2029.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
